William Blair Reiterates “Ourperform” Rating for Adamas Pharmaceuticals, Inc. (ADMS)
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “ourperform” rating reaffirmed by research analysts at William Blair in a report issued on Friday.
Other research analysts also recently issued reports about the stock. Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Cowen and Company set a $45.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Mizuho reaffirmed a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $33.00 target price (up previously from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $32.50.
Adamas Pharmaceuticals (NASDAQ ADMS) opened at 19.93 on Friday. The company’s market capitalization is $448.70 million. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $21.44. The company has a 50-day moving average price of $16.54 and a 200-day moving average price of $16.78.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the business posted ($0.78) earnings per share. The company’s revenue for the quarter was down 90.9% on a year-over-year basis. Analysts expect that Adamas Pharmaceuticals will post ($3.80) earnings per share for the current fiscal year.
In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of Adamas Pharmaceuticals stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new position in Adamas Pharmaceuticals during the second quarter worth $109,000. State Street Corp raised its position in Adamas Pharmaceuticals by 9.1% in the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock worth $4,990,000 after buying an additional 23,708 shares in the last quarter. Bamco Inc. NY raised its position in Adamas Pharmaceuticals by 45.5% in the second quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock worth $1,805,000 after buying an additional 32,272 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Adamas Pharmaceuticals by 11.9% in the second quarter. Dimensional Fund Advisors LP now owns 140,481 shares of the specialty pharmaceutical company’s stock worth $2,457,000 after buying an additional 14,987 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in Adamas Pharmaceuticals during the second quarter worth $184,000. 70.86% of the stock is owned by institutional investors and hedge funds.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.